Inventiva announces its 2025 annual financial results

Biopharmaceutical company Inventiva today announced the release of its 2025 financial results. These results will be published on March 30, 2026, after the close of U.S. markets. Specializing in the development of an oral therapy for steatohepatitis associated with metabolic dysfunction, Inventiva will hold a conference call to discuss these results. This conference, scheduled for March 31, 2026, will be followed by a question-and-answer session. Connection information for this live event will be available to registered participants. A recording will be accessible on Inventiva's website.